Journal
BLOOD
Volume 110, Issue 8, Pages 2838-2845Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2007-05-091280
Keywords
-
Categories
Funding
- NCI NIH HHS [P01 CA94237, P01 CA094237] Funding Source: Medline
- NCRR NIH HHS [U42 RR16578, U42 RR016578] Funding Source: Medline
Ask authors/readers for more resources
Epstein-Barr virus (EBV)-associated tumors developing in immunocompetent individuals present a challenge to immunotherapy, since they lack expression of immunodominant viral antigens. However, the tumors consistently express viral proteins including LMP2, which are immunologically weak but may nonetheless be targets for immune T cells. We previously showed that a majority of cytotoxic T lymphocytes (CTLs) reactivated using EBV-transformed B-lymphoblastoid cells lines (LCLs) contained minor populations of LMP2-specific T cells and homed to tumor sites. However, they did not produce remissions in patients with bulky disease. We have now used gene transfer into antigen-presenting cells (APCs) to augment the expression and immunogenicity of LMP2. These modified APCs increased the frequency of LMP2-specific CTLs by up to 100-fold compared with unmodified LCL-APCs. The LMP2-specific population expanded and persisted in vivo without adverse effects. Nine of 10 patients treated in remission of high-risk disease remain in remission, and 5 of 6 patients with active relapsed disease had a tumor response, which was complete in 4 and sustained for more than 9 months. it is therefore possible to generate immune responses to weak tumor antigens by ex vivo genetic modification of APCs and the CTLs; so produced can have substantial antitumor activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available